Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Barter

Showing results (371-380 of 390) with videos related to

Pageof 39
Sort By:
RNA (New York, N.Y.)|July 15, 2020
microRNA-seq of cartilage reveals an overabundance of miR-140-3p which contains functional isomiRsSteven Woods, Sarah Charlton, Kat Cheung, et al.
Diabetes Care|March 8, 2020
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart DiseaseGregory G Schwartz, Lawrence A Leiter, Christie M Ballantyne, et al.
The American Journal of Cardiology|January 12, 2005
Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)Diego F Wyszynski, Dawn M Waterworth, Philip J Barter, et al.
Journal of Clinical Lipidology|October 2, 2013
High-density lipoproteins: a consensus statement from the National Lipid AssociationPeter P Toth, Philip J Barter, Robert S Rosenson, et al.
Journal of the American Heart Association|August 5, 2017
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health StudyJulian C van Capelleveen, Andrea E Bochem, S Matthijs Boekholdt, et al.
Scientific Reports|May 18, 2021
Increased hippocampal excitability in miR-324-null miceDan J Hayman, Tamara Modebadze, Sarah Charlton, et al.
American Heart Journal|December 19, 2015
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trialStephen J Nicholls, A Michael Lincoff, Philip J Barter, et al.
The New England Journal of Medicine|November 7, 2007
Effects of torcetrapib in patients at high risk for coronary eventsPhilip J Barter, Mark Caulfield, Mats Eriksson, et al.
Clinical Cardiology|August 21, 2018
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trialStephen J Nicholls, A Michael Lincoff, Dianna Bash, et al.
The New England Journal of Medicine|November 7, 2012
Effects of dalcetrapib in patients with a recent acute coronary syndromeGregory G Schwartz, Anders G Olsson, Markus Abt, et al.
Pageof 39

Showing results (371-380 of 390) with videos related to

Sort By:
Pageof 39
RNA (New York, N.Y.)|July 15, 2020
microRNA-seq of cartilage reveals an overabundance of miR-140-3p which contains functional isomiRsSteven Woods, Sarah Charlton, Kat Cheung, et al.
Diabetes Care|March 8, 2020
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart DiseaseGregory G Schwartz, Lawrence A Leiter, Christie M Ballantyne, et al.
The American Journal of Cardiology|January 12, 2005
Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)Diego F Wyszynski, Dawn M Waterworth, Philip J Barter, et al.
Journal of Clinical Lipidology|October 2, 2013
High-density lipoproteins: a consensus statement from the National Lipid AssociationPeter P Toth, Philip J Barter, Robert S Rosenson, et al.
Journal of the American Heart Association|August 5, 2017
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health StudyJulian C van Capelleveen, Andrea E Bochem, S Matthijs Boekholdt, et al.
Scientific Reports|May 18, 2021
Increased hippocampal excitability in miR-324-null miceDan J Hayman, Tamara Modebadze, Sarah Charlton, et al.
American Heart Journal|December 19, 2015
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trialStephen J Nicholls, A Michael Lincoff, Philip J Barter, et al.
The New England Journal of Medicine|November 7, 2007
Effects of torcetrapib in patients at high risk for coronary eventsPhilip J Barter, Mark Caulfield, Mats Eriksson, et al.
Clinical Cardiology|August 21, 2018
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trialStephen J Nicholls, A Michael Lincoff, Dianna Bash, et al.
The New England Journal of Medicine|November 7, 2012
Effects of dalcetrapib in patients with a recent acute coronary syndromeGregory G Schwartz, Anders G Olsson, Markus Abt, et al.
Pageof 39